HOME > BUSINESS > Glenmark announces discovery of novel cancer drug

Glenmark announces discovery of novel cancer drug

Glenmark Pharmaceuticals has announced the discovery of a new anti-cancer therapy by its Swiss subsidiary.

drug-glenmark

The new drug, GBR 1302, will target breast cancer and ovarian cancer, and the company expects to start clinical studies this year.

Unlike normal drugs, the new drug will work by making it easier for human body’s defence mechanism, white blood cells, to identify and kill tumorous cells.

“The drug redirects cytotoxic T cells through its CD3 binding arm into HER2 expressing cancer cells and induces the killing of the cancer cells. The killing of the cancer cells by GBR 1302 is more rapid, more complete and not subject to the same resistance escape mechanisms as competing therapies,” Glenmark said.

The new drug is the first clinical development candidate evolved from Glenmark’s BEAT platform or bispecific engagement by antibodies based on the T cell receptor platform.

“For the past 20 years, bispecific antibodies have been a challenge to the industry since all bispecific formats developed so far have had stability or manufacturing issues. With the invention of the BEAT technology, Glenmark’s scientists have overcome these bottlenecks,” it said.

Follow ULTRA.news
Neuland Laboratories acquires Hyderabad factory from Arch Pharma Pharma manufacturer Neuland Laboratories said it acquired a manufacturing plant located near Hyderabad from Arch Pharma Labs Limited.The facility is spread across 12 acres and has a capacity of about 197 KL, the company said.The plant was inspected by the USFDA in 2015, ...
Glenmark starts trials of blood cancer drug Glenmark Pharmaceuticals said it has started the clinical trial of its blood cancer drug GBR 1342 with the dosing of the first patient.“In just the last year, three of the Company’s biologics, two of which are immuno-oncology agents, have begun clinical trials, which is a te...
DENGUE DEATH: Haryana govt probe finds Fortis Hospital guilty An official inquiry by the Haryana government has found the Gurgaon Fortis hospital guilty of overcharging and several other violations of law, media outlets reported.Quoting the official copy of the report, Mirror Now said that the inquiry committee found the hospital guilty...
Eris Lifesciences completes acquisition of Strides Shasun India generics ops Pharma company Eris LifeSciences said it has completed its purchase of the India branded generics of Strides Shasun for Rs 500 cr in cash."We now wish to confirm that the transaction ahs achieved closure," said Eris Lifesciences.Last month, Strides Shasun said it was sel...
Crucial win for Biocon as FDA approves cancer biosimilar trastuzumab Biocon and its partner Mylan scored a key victory on Friday as the US Food & Drug Administration approved its cancer-treating biosimilar trastuzumab."Mylan anticipates potentially being the first company to offer a biosimilar to Herceptin, as a result of Mylan's ability to s...
Boosted by Jio’s success, Mukesh Ambani unveils his future plans Mukesh Ambani, India's richest man, said telecom was the first of his big bet, and he will now use his resources to solve problems in three other difficult areas -- agriculture, education and healthcare.Speaking at the HT Leadership Summit, Ambani said his primary motivation...
Glenmark registers first inhaler product in Europe Glenmark Pharmaceuticals said it has registered its Seretide Accuhaler product in the Nordic region of Europe, including Sweden, Denmark, Norway, Finland and Iceland."The commercialization of the product would depend on national approval as well as substitution and pricing ...
EU accepts Biocon, Mylan’s application for cancer biosimilar pegfilgrastim Indian pharma company Biocon and its partner Mylan said EU authorities have accepted for review their applications for approving cancer treating biosimilars trastuzumab and pegfilgrastim submitted after completing corrective actions.The applications were resubmitted last mo...
Dr Reddy’s says EU approves production at Duvvada plant in Andhra Pharma major Dr Reddy's Laboratories said European Union authorities have again allowed it to produce drugs for sale in the EU region at its Duvvada factory in Andhra Pradesh.In its inspection conducted in September, the Regulatory Authority of Germany (Regierun von Oberbayer...
Panacea Biotec gets US nod for generic version of cancer drug Abraxane Panacea Biotec said it got the regulatory nod in the US for launching a generic version of big-selling cancer drug Abraxane.The drug will be sold with the help of Canadian pharmaceutical distributor Apotex.The annual sale of Abraxane worldwide is approximately US$973.4 m...
ICMR, Zydus launch diagnostic kits for infectious diseases Government of India-funded Indian Council of Medical Research (ICMR) and private sector player Zydus have announced the launch of new diagnostic kits that can help in detecting Japanese Encephalitis Virus in mosquitoes and the Crimean-Congo Haemorrhagic Fever in sheep, goat and ...
Dr Reddy’s gets served with class action lawsuit Pharma major Dr Reddy's Laboratories said it has been served with a class action lawsuit, originally announced in August, related to public disclosures made about regulatory action against the company."Further to our intimation dated August 28, 2017 with regard to US Securit...
Biocon launches colon cancer drug in India, priced Rs 24,000 Pharmaceutical company Biocon has launched KRABEVA, a biosimilar Bevacizumab for the treatment of patients a variety of cancers in India.The biosimilar -- or a drug that mimics a natural protein -- is useful in treating metastatic colorectal cancer and other types of lung, k...
Glenmark Pharma to launch birth control pill in USA Glenmark Pharmaceuticals said it got the approval of the United States Food & Drug Administration to launch a generic version of birth control pill Loestrin from Allergan Pharmaceuticals International.The drug had annual sales of approximately $116.8 million.The drug Nor...
Cipla gets US approval for cancer drug, Glenmark for oral contraceptive Two Indian pharmaceutical companies, Cipla and Glenmark, said they received approval from the US Food and Drug Administration for new drugs.While Cipla got the nod for a drug used to treat a type of blood cancer, Glenmark was approved to sell an oral contraceptive.Cipla...
Strides Shasun says Eris deal to help reprioritize business, lower debt Pharma major Strides Shasun said it agreed to sell its India branded generics business to Eris LifeSciences Limited for Rs 500 cr in cash."This transaction is the outcome of the company's portfolio reprioritization, to focus more sharply on larger regulated markets," it said...
Zydus gets nod for anti-inflammation drug in the US Pharma major Zydus Cadila said it received final approval from the USFDA to market an anti-inflammatory injection Ethacrynate Sodium in the US.The drug is used to decrease the Swelling (edema) caused by various disease conditions such as liver disease, kidney disease, conges...
Cipla launches ashtha inhaler therapy in the US Pharma giant Cipla Ltd said it received final approval for launching a generic version of Astrazeneca’s Pulmicort inhalation suspension for pediatric asthma in the US.The product is available for shipping immediately, Cipla said.Pulmicort Respules and generic equivalent...
Suven Life Sciences gets patents in USA, India and Hong Kong Pharma company Suven Life Sciences Ltd said it received new patents in India, USA and Hong Kong for neurological drugs.The patents -- one each in Hong Kong and the US and a couple in India -- are valid through 2032, 2030 and 2034."The granted claims of the patents include...
Zydus Cadila has an excellent quarter in Q2, PAT up 33% Pharma giant Zydus Cadila reported excellent numbers for the September quarter, led by rising US revenue that lifted its margins and profits.For the second quarter ended September 30, 2017, Zydus Cadila reported Earnings before Interest, Depreciation and Tax (EBIDTA) of Rs. 8...